Replies to post #111087 on Biotech Values

[ThomasS]

MNTA: I saw that. It is astounding to me that MNTA gets absolutely no credit whatsoever for entering the Lovenox generic market.
Nope, it's all about the "possibility" of another Lovenox entrant and zero credit for the pipeline (i.e., Copaxone)

[oldberkeley]

MNTA - Goldman Sachs starts coverage with a Neutral Rating and a 12-Month Price Target of $15

Love them or hate them, believe in the accuracy of their info or not, GS is on the list of the most closely followed analysts.

Very disappointing, won't help.